Ravulizumab (new indication: myasthenia gravis, patients who are anti-acetylcholine receptor (AChR) antibody-positive)



  • Active Substance: Ravulizumab 
  • Name: Ultomiris®
  • Therapeutic area: Myasthenia gravis
  • Pharmaceutical company: Alexion Pharma Germany GmbH


Time table:

  • Start: 01.11.2022
  • Publication of assessment: 01.02.2023
  • End of public hearing: 22.02.2023
  • Final decision by G-BA: middle of April 2023


Comparative therapy:

  1. Patients who are still eligible for standard therapy: therapy at the physician's discretion
  2. Patients who are not eligible for standard therapy: eculizumab